Micron Technologies Announces Acquisition by Arlington Capital

MALVERN, Pa. -- (BUSINESS WIRE) -- Micron Technologies, Inc. (www.microntech.com), a Malvern, Pennsylvania based company, today announced that it has been acquired by Arlington Capital Partners (www.arlingtoncap.com), a Washington, DC based private equity firm.

With locations in Malvern PA, USA and Dartford, UK, Micron Technologies is a leading international provider of particle size reduction and analytical services to the pharmaceutical industry. Micron provides first-class pharmaceutical micronization, milling and analytical services to more than 300 companies around the world and is a leader in air jet milling micronization. Micron has the capability of processing both R&D and commercial volumes alike and GMP facilities equipped with state of the art systems to ensure total product containment and quality.

“As a leading global service provider of particle reduction and analytical services, Micron Technologies continually strives to provide our client’s with best in class service. Leveraging the strong capabilities of the global Micron staff and the partnership with Arlington Capital, Micron is poised to expand our offering and exceed client expectations,“ commented Michael McDougal, Vice President Sales & Marketing.

Jean-Martin Larran – General Manager of Micron Technologies Ltd. commented, “The management team at Micron looks forward to working closely with Arlington Capital to utilize Micron Technologies as a platform to expand the business globally.”

Joseph Drost, CEO of Micron Technologies, commented, “We are extremely excited about our partnership with Arlington Capital. Arlington has a successful history of investing in healthcare and pharmaceutical services and shares our vision for growing Micron’s global capabilities and service offerings. Arlington’s ability to provide significant additional strategic and capital support will further enable Micron to continue to expand our leading global position and better serve our worldwide pharmaceutical client base.”

“Micron Technologies’ ability to provide leading bio-availability solutions across the drug development spectrum, from clinical phases to the commercial market, positions the Company as a trusted long-term partner with its pharmaceutical clients for their most demanding drug development needs,” said Matthew Altman, a Partner at Arlington Capital Partners. “We are enthusiastic about building upon the Company’s leadership position and eager to continue to support the Company as it enhances and expands its global particle size engineering and analytical service offerings.”

About Micron Technologies, Inc.

Micron Technologies provides advanced solubility enhancement services, primarily through particle size reduction and analytical services for pharmaceutical companies worldwide. Operating a new state-of-the-art 84,000 square foot cGMP facility in Malvern, PA and a 19,000 square foot cGMP facility in Dartford, U.K., Micron is uniquely positioned to serve the global needs of its clients from research and development to commercial scale volumes of APIs. Micron’s highly skilled workforce of approximately 100 employees utilize advanced equipment and possess unique expertise to perform various processes including jet milling, mechanical milling, containment processing and associated analytical services including material characterization testing and stability monitoring. www.microntech.com

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-based private equity firm with $1.5 billion of committed capital focused on middle market investment opportunities in growth industries including: healthcare services, aerospace/defense, government contracting, business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as leading competitors in their field. www.arlingtoncap.com